Neurofibromatosis type 1 with multiple tumors and intramedullary neurotuberculosis: a case report and diagnostic review
DOI:
https://doi.org/10.34119/bjhrv9n1-178Keywords:
neurofibromatosis type 1, meningioma, intramedullary tumors, neurotuberculosisAbstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder characterized by cutaneous and neurological manifestations and a predisposition to central and peripheral nervous system tumors. The coexistence of NF1 with multiple neuroaxis tumors and central nervous system infections, such as neurotuberculosis, is rare and represents a significant diagnostic and therapeutic challenge. We report the case of a young female patient with clinical and radiological findings consistent with NF1, presenting multiple intracranial lesions, including a sphenoid wing meningioma, who subsequently developed a cervical intramedullary lesion initially suspected to be neoplastic but ultimately confirmed as neurotuberculosis by histopathological and cerebrospinal fluid analyses. This case highlights the diagnostic difficulties in distinguishing neoplastic from infectious processes in patients with neurocutaneous syndromes and underscores the importance of integrated clinical, radiological, histopathological, and laboratory correlation.
References
FERNER, Rosalie E. et al. Neurofibromatosis type 1. In: AMINOFF, Michael J.; BOLLER, François; SWAAB, Dick F. (ed.). Handbook of Clinical Neurology. Amsterdam: Elsevier, 2013. v. 115, p. 939–955.
GUTMANN, David H. et al. Neurofibromatosis type 1. Nature Reviews Disease Primers, London, v. 3, art. 17004, 2017. DOI: 10.1038/nrdp.2017.4.
KOTCH, Chelsea; BROSIUS, Stephanie Nicole; DE RAEDT, Thomas; FISHER, Michael Jay. Updates in the management of central and peripheral nervous system tumors among patients with neurofibromatosis type 1 and neurofibromatosis type 2. Pediatric Neurosurgery, Basel, v. 58, n. 5, p. 267–280, 2023. DOI: 10.1159/000529507.
LEGIUS, Eric et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, New York, v. 23, n. 8, p. 1506–1513, 2021. DOI: 10.1038/s41436-021-01170-5.
LIU, Yu-Chen et al. Molecular targeted therapy for neurofibromatosis type 1, type 2, and schwannomatosis. International Journal of Molecular Sciences, Basel, v. 22, n. 11, art. 5850, 2021. DOI: 10.3390/ijms22115850.
ROCK, R. Bryson et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clinical Microbiology Reviews, Washington, v. 21, n. 2, p. 243–261, 2008. DOI: 10.1128/CMR.00042-07.
RUGGIERI, Martino; PRATICÒ, Antonino D.; CORSARO, Marco. Spinal and paraspinal manifestations of neurofibromatosis type 1. Child’s Nervous System, Berlin, v. 36, p. 2485–2503, 2020. DOI: 10.1007/s00381-020-04689-1.
THWAITES, Guy E.; VAN TOORN, Ronald; SCHOEMAN, Johan. Tuberculous meningitis: more questions, still too few answers. The Lancet Neurology, London, v. 12, n. 10, p. 999–1010, 2013. DOI: 10.1016/S1474-4422(13)70168-6.
WORLD HEALTH ORGANIZATION. Classification of Tumours Editorial Board. WHO classification of tumours of the central nervous system. 5. ed. Lyon: International Agency for Research on Cancer, 2021.
ZHAN, Zhixin et al. Neurofibroma and meningioma within a single dumbbell-shaped tumor at the same cervical level without neurofibromatosis: a case report and literature review. World Neurosurgery, New York, v. 130, p. e630–e636, 2019. DOI: 10.1016/j.wneu.2019.06.142.
